Figure 1From: Prognostic interaction between expression of p53 and estrogen receptor in patients with node-negative breast cancer: results from IBCSG Trials VIII and IXRemark diagram showing patients randomized to the parent clinical trials and those included in the present cohort for analysis of p53 expression. CMF, cyclophosphamide, methotrexate, 5-fluorouracil; FISH, fluorescent in situ hybridisation; HER, human epidermal growth factor receptor 2.Back to article page